We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIASORIN MOLECULAR

DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App




Simplexa Direct Test Includes 53 New Virus Strains

By LabMedica International staff writers
Posted on 20 Oct 2015
Print article
The 3M Integrated Cycler with assay kits
The 3M Integrated Cycler with assay kits (Photo courtesy of Diasorin Molecular)
The Simplexa test kit for select virus strains can detect a total of 92 influenza and respiratory syncytial virus (RSV) virus strains, more than any other officially cleared molecular test kit.

These include all four influenza strains that global health experts recommend be included in vaccines during the northern hemisphere’s 2015-2016 influenza season: A/Switzerland/9715293/2013 (H3N2)-like virus; A/California/7/2009 (H1N1)-like virus, B/Phuket/3073/2013-like virus, and B/Brisbane/60/2008-like virus.

In addition, the 46 new influenza strains include 20 avian influenza A and two swine influenza virus strains. These may be increasingly important to detect, as avian and swine influenza viruses can carry over into human populations. Influenza occurs globally, affecting an estimated 5% to 10% of adults and 20% to 30% of children, according to the World Health Organization (Geneva, Switzerland) statistics. Most seasonal flu activity in the Northern Hemisphere occurs between October and May, with peak season in the USA is between December and February.

The Simplexa Flu A/B & RSV Direct kit (Quest Diagnostics; Madison, NJ, USA) on the 3M Integrated Cycler (Focus diagnostics; Cypress, CA, USA) is a real-time reverse transcriptase polymerase chain reaction (RT-PCR) molecular test for the in vitro qualitative detection and differentiation of Influenza A virus, Influenza B virus, and respiratory syncytial virus (RSV) ribonucleic acid (RNA) in nasopharyngeal swabs from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors.

Classified as Clinical Laboratory Improvement Amendments (CLIA) moderate complexity, the test can report results in about an hour through a proprietary process that eliminates nucleic acid extraction, a time consuming technique typically employed by molecular tests. The tests have received from the US Food and Drug Administration (FDA, Silver springs, MD, USA) 510(k) initial clearance for combined molecular detection of influenza A, B and respiratory syncytial virus. Additional Simplexa tests aid in the detection and differentiation of influenza A, influenza B and RSV, Clostridium difficile, Group A Strep and Herpes simplex Virus (HSV) 1 and 2.

Related Links:

World Health Organization 
Quest Diagnostics 
Focus diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.